產品名稱：Escherichia coli O157:H7 / E.coli O157:H7 ELISA Kit
- 產品編號
- BEK1249
- 產品規格
- 96T
- 價格
- 2200.00
- 來源
- -
- 交叉反應
- E.coli
- 免 疫 原
- -
- 產品簡介
- This kit was based on sandwich enzyme-linked immune-sorbent assay technology. Anti-E.coli O157:H7 monoclonal antibody was pre-coated onto 96-well plates. And the HRP conjugated anti-E.coli O157:H7 polyclonal antibody was used as detection antibodies. The standards, test samples and HRP conjugated detection antibody were added to the wells subsequently, and wash with wash buffer. TMB substrates were used to visualize HRP enzymatic reaction. TMB was catalyzed by HRP to produce a blue color product that changed into yellow after adding acidic stop solution. The density of yellow is proportional to the E.coli O157:H7 amount of sample captured in plate. Read the O.D. absorbance at 450nm in a microplate reader, and then the concentration of E.coli O157:H7 can be calculated.
Kit components
1. One 96-well plate pre-coated with anti-E.coli O157:H7 antibody
2. Lyophilized E.coli O157:H7 standards: 2 tubes (4 × 105 cfu / tube)
3. Sample diluent buffer: 30 ml
4. HRP conjugated anti-E.coli O157:H7 antibody (Concentrated): 130 μl. Dilution: 1:100
5. Antibody diluent buffer: 12 ml
6. TMB substrate: 10 ml
7. Stop solution: 10 ml
8. Wash buffer: 30 ml (25x). Dilution: 1:25
Note: Reconstitute standards and test samples with Kit Component 3.
- 產品別名
- -
- 產品成分
- -
- 檢測范圍
- 6.25 × 103?cfu/ml - 4 ×105?cfu/ml
- 檢測樣品
- For quantitative detection of E.coli O157:H7 in food or water.
- 產品應用
- ELISA
- 保存條件
- 2-8℃6個月 -20℃一年
- 背景資料
- Escherichia coli O157:H7 is an enterohemorrhagic serotype of the bacterium Escherichia coli and a cause of illness, typically through consumption of contaminated food. As an emerging pathogen, Escherichia coli O157:H7 causes severe enteritis and the extraintestinal complication of hemolytic-uremic syndrome. Rokhsartalab-Azar S et al evaluate the conjugate of E. coli O157: H7 lipopolysaccharide (LPS) with diphtheria toxoid (DT) as a candidate vaccine in mice model. Their results showed that the suggested vaccine composed of E. coli O157:H7 LPS and DT had a significant potential to protect against E. coli infections. Infection with Escherichia coli O157:H7 may develop into hemorrhagic colitis, or hemolytic uremic syndrome (HUS), which usually causes kidney failure or even death. The adhesion and toxins are the important virulent factors. Cai K et al constructed a novel vaccine candidate rSOBGs based on the bacterial ghost (BG). They found the novel vaccine candidate rSOBGs induced both anti-toxin and anti-adhesion immune protection, suggesting the possibility to prevent the infectious diseases caused by Escherichia coli O157:H7.
- 參考資料
- 1. Karch H, Tarr P, Bielaszewska M (2005). "Enterohaemorrhagic Escherichia coli in human medicine.". Int J Med Microbiol 295 (6–7): 405–18. 2. Rokhsartalab-Azar S, Shapouri R, Rahnema M, Najafzadeh F, Kianmehr A. Synthesis, characterization and immunological properties of Escherichia coli 0157:H7 lipopolysaccharide- diphtheria toxoid conjugate vaccine. Iran J Microbiol. 2015 Jun;7(3):150-5. 3. Cai K, Tu W, Liu Y, Li T, Wang H. Novel fusion antigen displayed-bacterial ghosts vaccine candidate against infection of Escherichia coli O157:H7. Sci Rep. 2015 Dec 2;5:17479.
